Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, noviembre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Telix Pharmaceuticals Ltd
TLX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.37
-0.34
-3.9%
al cierre: Nov 20, 4:00 PM EST
$8.37
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Telix Pharmaceuticals Financials
Telix Pharmaceuticals (TLX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Reported Earlier, Telix Reaffirms FY 2026 Revenue And Other Income Above $1B, Tracking Toward Upper End Of $950M-$970M Revenue Guidance, Revises R&D Spend Guidance To $240M-$260M
Benzinga Newsdesk
PRO
Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand
Benzinga Newsdesk
PRO
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
GuidanceFY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue progressing in line with the upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of
Benzinga Newsdesk
PRO
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
Benzinga Newsdesk
PRO
Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY
Benzinga Newsdesk
Why Is Telix Pharma Stock Soaring Tuesday?
Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratings with price targets up to $22.00.
Vandana Singh